Cefditoren pivoxil - Meiji Seika Pharma
Alternative Names: CDN; CDN-PI; CDTR-PI; CRTX-062; CRTX-068; ME-1207; Meiact; Meiact MS Fine Granules 10% - Meiji Seika Pharma; SpectracefLatest Information Update: 28 Feb 2024
At a glance
- Originator Meiji Seika Kaisha
- Developer Cornerstone Therapeutics; Meiji Seika Pharma; Tedec Meiji
- Class Anti-infectives; Antibacterials; Cephems; Small molecules
- Mechanism of Action Cell wall inhibitors; Interleukin 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Acute exacerbations of chronic bronchitis; Bacterial infections; Community-acquired pneumonia; Otitis media; Respiratory tract infections; Skin and soft tissue infections; Tonsillitis
- Suspended Pharyngitis
- No development reported COVID-19 pneumonia; Urinary tract infections
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for clinical-Phase-Unknown development in COVID-19 pneumonia(In adults) in Spain (PO)
- 05 Jan 2021 Clinical trials in COVID-19 pneumonia (In adults) in Spain (PO) in January 2021 (NCT04709172)
- 01 Aug 2019 Launched for Bacterial infections (In children) in Indonesia (PO)